Bupa to support effective medication through pharmacogenomics program

In an Australian first, Bupa has today announced an offer of free pharmacogenomic testing kits* until the end of the year for its health insurance customers to understand how their individual genetic profile may affect their response to more than 100 different medications.

 

Bupa is partnering with myDNA to offer interested health insurance customers pharmacogenomic testing through Bupa’s digital health platform, Blua and at Bupa’s Medical Centres. The general public will also be able to access the test through Blua at a discounted rate.

 

Pharmacogenomics provides doctors with insights into how an individual person’s body is likely to respond to certain medications. The test looks at 11 key genes that affect how the body responds to more than 100 medications, including mental health, heart health, cholesterol management and pain management. 

 

Tests are done via a simple cheek swab with customers able to order an ‘at home’ kit through Blua. The results will be sent to the customer’s nominated GP and customers will be required to attend an appointment with their GP to discuss the results, and cover the cost of their consultation.

 

Bupa Clinical Innovation and Genomics Director Dr Simon Benson said pharmacogenomic testing was designed to offer clinicians a more accurate understanding of their individual patients’ response to medication to help support more effective prescribing.

 

“Currently, medications are prescribed without knowing how an individual’s genetic makeup may impact their response to the medication. Sometimes finding the right medication can require some trial-and-error. Pharmacogenomic testing can help inform medication choices, reduce side effects, and limit unnecessary healthcare cost,” Dr Benson said.

 

“Pharmacogenomics can provide information to support healthcare providers and patients in understanding how an individual may respond to certain medications, helping to inform more personalised treatment decisions."

 

If a customer chooses to undergo pharmacogenomic testing this will have no impact on an individual’s health insurance premium and results will not be shared with Bupa Health Insurance.

 

Pharmacogenomic results can help the GP make an informed decision if prescribing a new medication or guide them in making changes to an existing treatment. This could include increasing or lowering dosages or switching to an alternate medication or treatment.

 

A person’s pharmacogenomic profile stays the same throughout their life, so test results can also be used to guide future treatment decisions.

 

Alongside pharmacogenomics results, doctors also take other factors into account when choosing the most appropriate medication for a patient, including their lifestyle, age, overall health and use of other medications.

 

Dr Benson said pharmacogenomics could help ease pressure on the health system as it had the potential to reduce avoidable hospital admissions and return GP visits linked to individual’s problems with medications.

 

“The results of an individual’s pharmacogenetic testing need to be discussed with their GP as part of their ongoing treatment plan,” he said.

 

“Finding the right medication and reducing side effects with guidance from healthcare professionals can potentially help increase patient adherence to treatment plans and contribute to improved health outcomes.”

 

myDNA co-founder Allan Sheffield said: “We firmly believe that pharmacogenomics testing should be a standard part of care for all Australians, which could help doctors provide more effective, personalised health outcomes."

 

*Bupa is partnering with myDNA to offer Bupa Health Insurance members, who are 18+ and live in Australia, a free pharmacogenomics test kit and the general public can receive a $49 discount to purchase the kit for $149 in total through Blua. To qualify for free testing, customers need to order test kits by November 30, 2025, and have the sample returned by December 31, 2025. Free testing kits will be limited to 10,000 kits. GP appointments to review the results will be paid for by the customer.

 

ENDS

 

Note to News Desks:

 

Interviews available with:

• Case study
• Bupa Clinical Innovation and Genomics Director Dr Simon Benson
• myDNA co-founder Allan Sheffield

 

For more information, please contact:
Aleks Devic                                                          
Head of External Communications                                 
Email: [email protected]     

Mob: 0412 868 933                                                            

 

 

About Bupa Asia Pacific

Bupa is an international healthcare group which has been committed to a purpose of helping people live longer, healthier, happier lives and making a better world for more than 70 years.

Bupa Asia Pacific operates in Australia, New Zealand and Hong Kong, supporting about 7.3 million customers through a broad range of health and care services including health insurance, aged care, dental, medical, optical and hearing services.

Employing more than 22,000 people in the region, we believe that we can make a real difference to the lives of customers through our values, purpose and the way that we deliver personalised care.

Over the past 17+ years we have invested more than AUD$36 million in partnerships and programs focused on improving health of communities across Australia.

About myDNA

Our mission is to make precision health services standard care for a healthier world

 

myDNA is a world leader in precision health, delivering clinically validated insights to support healthcare providers, laboratories, and health systems. Our solutions enable personalised prescribing, risk stratification, and preventative care, advancing healthcare from reactive to proactive. Through continuous innovation, we support the global shift toward data-driven, individualised healthcare.

 

myDNA success is driven by a dedicated team of pharmacogenomic specialists, including clinical geneticists, clinical pharmacologists, bioinformaticians, and pharmacists. This expertise allows them to provide leading pharmacogenomic reporting solutions across the globe.